Modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh: 36-month follow-up

Background: There is an ongoing debate on the role of comorbidities in hernia outcomes, particularly with minimally invasive approaches. This study evaluated the impact of modifiable comorbidities (MCMs) on 36-month hernia recurrence rates after robotic transversus abdominis release (TAR) with resor...

Full description

Bibliographic Details
Main Authors: Alexandra C. Skoczek, Patrick W. Ruane, Dennis L. Fernandez
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Surgery Open Science
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589845023000441
_version_ 1797774481928749056
author Alexandra C. Skoczek
Patrick W. Ruane
Dennis L. Fernandez
author_facet Alexandra C. Skoczek
Patrick W. Ruane
Dennis L. Fernandez
author_sort Alexandra C. Skoczek
collection DOAJ
description Background: There is an ongoing debate on the role of comorbidities in hernia outcomes, particularly with minimally invasive approaches. This study evaluated the impact of modifiable comorbidities (MCMs) on 36-month hernia recurrence rates after robotic transversus abdominis release (TAR) with resorbable biosynthetic mesh underlay for primary ventral hernia repair. Methods: A review of medical records for patients who underwent the robotic TAR procedure between January 2015 and May 2022 performed by a single surgeon was conducted. Patients were separated into three groups: those with 0, 1, and 2+ MCMs, followed by a breakdown of comorbidity types and combinations of comorbidities. MCMs included obesity, diabetes, and tobacco use. The primary outcomes included hernia recurrence at 36 months and the time between surgery and recurrence. Results: 175 patients met the inclusion criteria, with a mean hernia diameter of 12.9 ± 5.4 cm and a mean BMI of 34 ± 8 kg/m2. 9.7 % of patients experienced hernia recurrence at 36-month follow-up. No significant difference in the recurrence rate and length of time between surgery and recurrence was observed between the groups (p = .265 and p = .283, respectively). No group, single comorbidity, or a combination of comorbidities was found to have significantly increased odds of recurrence at 36 months. Conclusion: The presence of MCMs, either alone or in combination with another, did not significantly increase the odds of hernia recurrence at 36 months following ventral hernia repair using this approach. Future studies with larger sample sizes and multiple surgeons are needed to corroborate this data. Key message: Modifiable comorbidities have previously been shown to increase the risk of hernia recurrence after ventral hernia repair. Our study found relatively low rates of hernia recurrence and no significantly increased odds of recurrence among different comorbid groups at 36-month follow-up following robotic transversus abdominis release with resorbable biosynthetic mesh underlay.
first_indexed 2024-03-12T22:21:45Z
format Article
id doaj.art-5ee024945d1145bf809b49dcc248801c
institution Directory Open Access Journal
issn 2589-8450
language English
last_indexed 2024-03-12T22:21:45Z
publishDate 2023-08-01
publisher Elsevier
record_format Article
series Surgery Open Science
spelling doaj.art-5ee024945d1145bf809b49dcc248801c2023-07-23T04:56:11ZengElsevierSurgery Open Science2589-84502023-08-01146065Modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh: 36-month follow-upAlexandra C. Skoczek0Patrick W. Ruane1Dennis L. Fernandez2Edward Via College of Osteopathic Medicine – Auburn, Auburn, AL, United States; Corresponding author at: Edward Via College of Osteopathic Medicine – Auburn, 910 S Donahue Dr., Auburn, AL 36830, United States.Edward Via College of Osteopathic Medicine – Carolinas, Spartanburg, SC, United StatesCrestwood Medical Center, Huntsville, AL, United StatesBackground: There is an ongoing debate on the role of comorbidities in hernia outcomes, particularly with minimally invasive approaches. This study evaluated the impact of modifiable comorbidities (MCMs) on 36-month hernia recurrence rates after robotic transversus abdominis release (TAR) with resorbable biosynthetic mesh underlay for primary ventral hernia repair. Methods: A review of medical records for patients who underwent the robotic TAR procedure between January 2015 and May 2022 performed by a single surgeon was conducted. Patients were separated into three groups: those with 0, 1, and 2+ MCMs, followed by a breakdown of comorbidity types and combinations of comorbidities. MCMs included obesity, diabetes, and tobacco use. The primary outcomes included hernia recurrence at 36 months and the time between surgery and recurrence. Results: 175 patients met the inclusion criteria, with a mean hernia diameter of 12.9 ± 5.4 cm and a mean BMI of 34 ± 8 kg/m2. 9.7 % of patients experienced hernia recurrence at 36-month follow-up. No significant difference in the recurrence rate and length of time between surgery and recurrence was observed between the groups (p = .265 and p = .283, respectively). No group, single comorbidity, or a combination of comorbidities was found to have significantly increased odds of recurrence at 36 months. Conclusion: The presence of MCMs, either alone or in combination with another, did not significantly increase the odds of hernia recurrence at 36 months following ventral hernia repair using this approach. Future studies with larger sample sizes and multiple surgeons are needed to corroborate this data. Key message: Modifiable comorbidities have previously been shown to increase the risk of hernia recurrence after ventral hernia repair. Our study found relatively low rates of hernia recurrence and no significantly increased odds of recurrence among different comorbid groups at 36-month follow-up following robotic transversus abdominis release with resorbable biosynthetic mesh underlay.http://www.sciencedirect.com/science/article/pii/S2589845023000441Hernia, abdominalRoboticsComorbidityPostoperative complicationsObesityAbdominal, wall
spellingShingle Alexandra C. Skoczek
Patrick W. Ruane
Dennis L. Fernandez
Modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh: 36-month follow-up
Surgery Open Science
Hernia, abdominal
Robotics
Comorbidity
Postoperative complications
Obesity
Abdominal, wall
title Modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh: 36-month follow-up
title_full Modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh: 36-month follow-up
title_fullStr Modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh: 36-month follow-up
title_full_unstemmed Modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh: 36-month follow-up
title_short Modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh: 36-month follow-up
title_sort modifiable comorbidities impact on ventral hernia recurrence following robotic abdominal wall reconstruction using resorbable biosynthetic mesh 36 month follow up
topic Hernia, abdominal
Robotics
Comorbidity
Postoperative complications
Obesity
Abdominal, wall
url http://www.sciencedirect.com/science/article/pii/S2589845023000441
work_keys_str_mv AT alexandracskoczek modifiablecomorbiditiesimpactonventralherniarecurrencefollowingroboticabdominalwallreconstructionusingresorbablebiosyntheticmesh36monthfollowup
AT patrickwruane modifiablecomorbiditiesimpactonventralherniarecurrencefollowingroboticabdominalwallreconstructionusingresorbablebiosyntheticmesh36monthfollowup
AT dennislfernandez modifiablecomorbiditiesimpactonventralherniarecurrencefollowingroboticabdominalwallreconstructionusingresorbablebiosyntheticmesh36monthfollowup